全文获取类型
收费全文 | 1703272篇 |
免费 | 124717篇 |
国内免费 | 3794篇 |
专业分类
耳鼻咽喉 | 21837篇 |
儿科学 | 55862篇 |
妇产科学 | 46314篇 |
基础医学 | 242528篇 |
口腔科学 | 48856篇 |
临床医学 | 152124篇 |
内科学 | 334925篇 |
皮肤病学 | 39040篇 |
神经病学 | 132086篇 |
特种医学 | 64202篇 |
外国民族医学 | 244篇 |
外科学 | 258669篇 |
综合类 | 39019篇 |
现状与发展 | 4篇 |
一般理论 | 532篇 |
预防医学 | 124809篇 |
眼科学 | 40329篇 |
药学 | 124158篇 |
7篇 | |
中国医学 | 4510篇 |
肿瘤学 | 101728篇 |
出版年
2021年 | 12907篇 |
2019年 | 13635篇 |
2018年 | 20088篇 |
2017年 | 15332篇 |
2016年 | 16748篇 |
2015年 | 19127篇 |
2014年 | 26389篇 |
2013年 | 38226篇 |
2012年 | 53126篇 |
2011年 | 55860篇 |
2010年 | 33042篇 |
2009年 | 30947篇 |
2008年 | 51860篇 |
2007年 | 55205篇 |
2006年 | 55636篇 |
2005年 | 52938篇 |
2004年 | 51072篇 |
2003年 | 48492篇 |
2002年 | 46691篇 |
2001年 | 92076篇 |
2000年 | 93864篇 |
1999年 | 77169篇 |
1998年 | 19843篇 |
1997年 | 17365篇 |
1996年 | 17455篇 |
1995年 | 16804篇 |
1994年 | 15344篇 |
1993年 | 14123篇 |
1992年 | 57506篇 |
1991年 | 55400篇 |
1990年 | 53063篇 |
1989年 | 50868篇 |
1988年 | 46275篇 |
1987年 | 45045篇 |
1986年 | 42344篇 |
1985年 | 40081篇 |
1984年 | 29428篇 |
1983年 | 24991篇 |
1982年 | 13957篇 |
1979年 | 25589篇 |
1978年 | 17626篇 |
1977年 | 14959篇 |
1976年 | 13919篇 |
1975年 | 14621篇 |
1974年 | 17688篇 |
1973年 | 17011篇 |
1972年 | 15722篇 |
1971年 | 14512篇 |
1970年 | 13484篇 |
1969年 | 12555篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
121.
Alexander S. Dakos Ellen M. Walker Huai Jiang Barry E. Stein Benjamin A. Rowland 《The European journal of neuroscience》2019,50(11):3702-3712
Unilateral lesions of visual cortex have the secondary consequence of suppressing visual circuits in the midbrain superior colliculus (SC), collectively producing blindness in contralesional space (“hemianopia”). Recent studies have demonstrated that SC visual responses and contralesional vision can be reinstated by a non‐invasive multisensory training procedure in which spatiotemporally concordant visual‐auditory pairs are repeatedly presented within the blind hemifield. Despite this recovery of visual responsiveness, the loss of visual cortex was expected to result in permanent deficits in that hemifield, especially when visual events in both hemifields compete for attention and access to the brain's visuomotor circuitry. This was evaluated in the present study in a visual choice paradigm in which the two visual hemifields of recovered cats were simultaneously stimulated with equally valent visual targets. Surprisingly, the expected disparity was not found, and some animals even preferred stimuli presented in the previously blind hemifield. This preference persisted across multiple stimulus intensity levels and there was no indication that animals were less aware of cues in the previously blind hemifield than in its spared counterpart. Furthermore, when auditory cues were combined with visual cues, the enhanced performance they produced on a visual task was no greater in the normal than in the previously blind hemifield. These observations suggest that the multisensory rehabilitation paradigm revealed greater inherent visual information processing potential in the previously blind hemifield than was believed possible given the loss of visual cortex. 相似文献
122.
Toidi Adekambi Chris C. Ibegbu Stephanie Cagle Ameeta S. Kalokhe Yun F. Wang Yijuan Hu Cheryl L. Day Susan M. Ray Jyothi Rengarajan 《The Journal of clinical investigation》2015,125(5):1827-1838
BACKGROUND. The identification and treatment of individuals with tuberculosis (TB) is a global public health priority. Accurate diagnosis of pulmonary active TB (ATB) disease remains challenging and relies on extensive medical evaluation and detection of Mycobacterium tuberculosis (Mtb) in the patient’s sputum. Further, the response to treatment is monitored by sputum culture conversion, which takes several weeks for results. Here, we sought to identify blood-based host biomarkers associated with ATB and hypothesized that immune activation markers on Mtb-specific CD4+ T cells would be associated with Mtb load in vivo and could thus provide a gauge of Mtb infection.METHODS. Using polychromatic flow cytometry, we evaluated the expression of immune activation markers on Mtb-specific CD4+ T cells from individuals with asymptomatic latent Mtb infection (LTBI) and ATB as well as from ATB patients undergoing anti-TB treatment.RESULTS. Frequencies of Mtb-specific IFN-γ+CD4+ T cells that expressed immune activation markers CD38 and HLA-DR as well as intracellular proliferation marker Ki-67 were substantially higher in subjects with ATB compared with those with LTBI. These markers accurately classified ATB and LTBI status, with cutoff values of 18%, 60%, and 5% for CD38+IFN-γ+, HLA-DR+IFN-γ+, and Ki-67+IFN-γ+, respectively, with 100% specificity and greater than 96% sensitivity. These markers also distinguished individuals with untreated ATB from those who had successfully completed anti-TB treatment and correlated with decreasing mycobacterial loads during treatment.CONCLUSION. We have identified host blood-based biomarkers on Mtb-specific CD4+ T cells that discriminate between ATB and LTBI and provide a set of tools for monitoring treatment response and cure.TRIAL REGISTRATION. Registration is not required for observational studies.FUNDING. This study was funded by Emory University, the NIH, and the Yerkes National Primate Center. 相似文献
123.
Jenny U. Johansson Nathaniel S. Woodling Qian Wang Maharshi Panchal Xibin Liang Angel Trueba-Saiz Holden D. Brown Siddhita D. Mhatre Taylor Loui Katrin I. Andreasson 《The Journal of clinical investigation》2015,125(1):350-364
Microglia, the innate immune cells of the CNS, perform critical inflammatory and noninflammatory functions that maintain normal neural function. For example, microglia clear misfolded proteins, elaborate trophic factors, and regulate and terminate toxic inflammation. In Alzheimer’s disease (AD), however, beneficial microglial functions become impaired, accelerating synaptic and neuronal loss. Better understanding of the molecular mechanisms that contribute to microglial dysfunction is an important objective for identifying potential strategies to delay progression to AD. The inflammatory cyclooxygenase/prostaglandin E2 (COX/PGE2) pathway has been implicated in preclinical AD development, both in human epidemiology studies and in transgenic rodent models of AD. Here, we evaluated murine models that recapitulate microglial responses to Aβ peptides and determined that microglia-specific deletion of the gene encoding the PGE2 receptor EP2 restores microglial chemotaxis and Aβ clearance, suppresses toxic inflammation, increases cytoprotective insulin-like growth factor 1 (IGF1) signaling, and prevents synaptic injury and memory deficits. Our findings indicate that EP2 signaling suppresses beneficial microglia functions that falter during AD development and suggest that inhibition of the COX/PGE2/EP2 immune pathway has potential as a strategy to restore healthy microglial function and prevent progression to AD. 相似文献
124.
125.
A. Hochsprung S. Escudero-Uribe A.J. Ibáñez-Vera G. Izquierdo-Ayuso 《Neurología (Barcelona, Spain)》2021,36(6):433-439
IntroductionPain is highly prevalent in patients with multiple sclerosis (MS); it is chronic in 50% of cases and is classified as nociceptive, neuropathic, or mixed-type. Pain affects quality of life, sleep, and the activities of daily living. Electrotherapy is an interesting alternative or complementary treatment in the management of pain in MS, with new innovations constantly appearing.Material and methodsThis study evaluates the effectiveness of treatment with monopolar dielectric transmission of pulsed electromagnetic fields (PEMF) for pain associated with MS. We performed a randomised, placebo-controlled clinical trial including 24 patients, who were assessed with the Brief Pain Inventory, the Multiple Sclerosis International Quality of Life questionnaire, the Beck Depression Inventory, and the Modified Fatigue Impact Scale.ResultsStatistically significant improvements were observed in maximum and mean pain scores, as well as in the impact of pain on work, personal relationships, and sleep and rest. Not significant differences were found between the treatment and placebo groups.ConclusionsTreatment with PEMF may be effective in reducing pain in patients with MS, although further research is necessary to confirm its effectiveness over placebo and to differentiate which type of pain may be more susceptible to this treatment. 相似文献
126.
127.
128.
129.
130.